|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/47 | (2006.01) |
| A61K 31/675 | (2006.01) | ||
| A61K 31/7048 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Patento numeris | 3338779 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16837150.8 |
| Europos patento paraiškos padavimo data | 2016-08-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-06-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-06-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/JP2016/074090 |
| Data | 2016-08-18 |
| (87) | Numeris | WO 2017/030161 |
| Data | 2017-02-23 |
| (30) | Numeris | Data | Šalis |
| 201562207546 P | 2015-08-20 | US |
| (72) |
OKAMOTO, Kiyoshi , JP
MATSUI, Junji , JP
DUTCUS, Corina , US
|
| (73) |
Eisai R&D Management Co., Ltd. ,
4-6-10 Koishikawa
Bunkyo-ku, Tokyo 112-8088,
JP
|
| (54) | LENVATINIB IN COMBINATION WITH ETOPOSIDE AND IFOSFAMIDE FOR USE IN TREATING A TUMOR |
| LENVATINIB IN COMBINATION WITH ETOPOSIDE AND IFOSFAMIDE FOR USE IN TREATING A TUMOR |